The humanised monoclonal antibody (mAb) Herceptin, which specifically targets HER-2, exhibits potent growth inhibitory activity against HER-2-over expressing tumours (Sliwkowski et al, 1999). This evidence concerns the gene ERBB2 and neoplasm.